A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
for Advanced Solid Tumors
11 locations incl. Aurora
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Sex: All·Age: 18+
Code: NCT06384352·Phase 1·Recruiting